Ms. Walter graduated from the University of Alberta in Canada and received a master’s degree In Public Administration from the University of Victoria in British Columbia. Her articles have appeared in several medical journals and in various reports. Since 2018 she has served as Senior Director, U.S. Public Policy and Government Affairs, for Greenwich Biosciences (GW), one of the first companies in the world to develop cannabis-derived medications as prescription products in adherence to modern scientific and regulatory standards for pharmaceutical products. She leads GW’s federal public policy and legislative efforts, as well as works with advocacy organizations across numerous therapeutic areas. Prior to GW, Ms. Walter worked at Takeda Pharmaceuticals where she was heavily engaged in Medicare issues in both the regulatory and legislative arenas. She directed the company’s strategic policy engagement in coverage and insurance, market delivery and payment systems, and financing strategies, as well as employer risk-based sharing contracts. During her tenure as a health economist with the Medicare Payment Advisory Commission (MedPAC), an independent federal body that advises the U.S. Congress on issues affecting the Medicare program, she analyzed Medicare policies affecting hospitals and skilled nursing facilities, and made recommendations for payment reforms to the Congress.